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REPORT ON A PILOT STUDY OF THE SIMPILL REALTIME MEDICATION 
ADHERENCE SYSTEM IN TUBERCULOSIS PATIENTS IN CAPE TOWN, 
SOUTH AFRICA
Green D1, Tsodzo C2
1Liberty Health Holdings, Hout Bay, South Africa; 2Ruhr-Universität Bochum, Bochum, 
Germany
OBJECTIVES: SIMpill is a medication adherence management system using cellular 
networks to provide real-time information about, and support to, patients on long 
term medication. The SIMpill system is described in detail. METHODS: A pilot was 
carried out from July 1, 2006 to April 12, 2007 in Cape Town, South Africa. Patients 
diagnosed with Tuberculosis were taken onto the pilot as they arrived at the clinics 
until the desired number of patients was achieved. Contrary to the standard DOTS 
protocol, patients were allowed to self medicate either at their homes or their places 
of work, supported by the SIMpill system. RESULTS: Of the 155 TB patients enrolled 
in the pilot study the following results were recorded: 12 patients (8%) did not have 
adequate documentation of outcomes at the end of the pilot and are excluded from 
the data. One patient (0.8%) was recorded as a sputum positive treatment failure. 
Seven patients (3.3%) interrupted their treatment whilst four patients transferred to 
other clinics or died during the pilot study. a total of 131 patients (91.6% including 
unrelated interruptions, 94.2% excluding unrelated interruptions) were recorded as 
successful treatments. This is contrasted with the background treatment success rate 
under the DOTS regimen of 76.4% at the same time in the same communities. 
CONCLUSIONS: It is concluded that the SIMpill system is practical to implement, 
could dramatically improve treatment success in TB patients and warrants further 
study, both in TB and other conditions.
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DEVELOPMENT OF A SPECIFIC QUESTIONNAIRE TO ASSESS 
TREATMENT ADHERENCE OF PATIENTS WITH HCV INFECTION: 
ADHEPTA STUDY
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OBJECTIVES: Treatment adherence is a key issue in chronic infectious diseases such 
as Chronic Hepatitis C (CHC). The aim of the study was to develop two valid and 
feasible disease speciﬁ c questionnaires to assess adherence to treatment of CHC 
monoinfected patients and HCV/HIV co-infected patients. METHODS: Question-
naires development was carried out in two phases. In the ﬁ rst phase, a literature review 
was performed in order to identify factors closely related to treatment adherence. By 
means of a focus group, disease experts selected the items considered most likely to 
affect adherence from the initial list, then the chosen items underwent a qualitative 
analysis and were rephrased to make them suitable for inclusion in a questionnaire. 
The ﬁ rst version of the questionnaires was completed by 18 patients (8 monoinfected 
and 10 co-infected) in order to evaluate the comprehension of questions, response 
categories, questionnaires applicability and the patients’ opinion on the proposed 
questionnaires design. The questionnaires are currently being validated in the second 
phase, an ongoing prospective study including 1120 patients. RESULTS: The two 
questionnaires developed for monoinfected and for co-infected patients contained 11 
and 13 questions, respectively. Both questionnaires included two questions related to 
treatment adherence and questions about reasons of non-adherence. To date 843 
patients have been included in the prospective study; 71.9% are male, 77.1% are 
monoinfected patients, 22.9% co-infected and 63.0% of patients have baseline 
RNA-HCV > 800.000 UI/ml (62.1% monoinfected and 66.1% co-infected). The HCV 
genotype distribution is 74.8% G-1/4 and 25.7% G-2/3. The HIV positive patients 
receiving ART Therapy are 91.2%. CONCLUSIONS: The two disease speciﬁ c ques-
tionnaires developed to assess adherence to treatment showed feasibility and good 
comprehension by patients with HCV monoinfection and with HCV/HIV co-infection, 
respectively. Further validation is ongoing in a prospective study.
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CLINICAL PROFILE AND ADHERENCE PATTERN OF ANTI-RETROVIRAL 
THERAPY OF PEOPLE LIVING WITH HIV/AIDS REGISTERED AT 
DISTRICT ANTI RETROVIRAL THERAPY CENTRE, UDUPI DISTRICT
Singh UP, Nayak GC, Singh S, Rath S, Bihan A, Kumar M
Manipal College of Pharmaceutical Sciences, Manipal, India
OBJECTIVES: To ﬁ nd out the number of people infected with AIDS, the age group 
that was badly hit by this disease, the number of deaths and most important of all 
the adherence shown by the patient to the treatment regimen. METHODS: Study 
subjects: All the people living with HIV/AIDS who were started on Anti Retroviral 
Therapy at the District ART Centre, Udupi District from 1st July, 2008 to 31st June, 
2009. Case ﬁ les were reviewed from medical records section and required data was 
collected and analyzed using SPSS 11.5 version. RESULTS: Study included 946 cases 
of which majority were males 534 and 815 were in the age-group of 15–49. 836 were 
residents of Udupi District. CONCLUSIONS: All of them were started on ART and 
have been on treatment for atleast 3 months. More than 90% of the patients had 
adherence of more than 95%.
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AN ECONOMIC EVALUATION OF HIBMENCY VACCINATION FOR THE 
PREVENTION OF HEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA 
MENINGITIDIS TYPES C AND Y
Taylor MJ1, Saxby RC1, Abu-Elyazeed RR2, Misurski DA3
1University of York, York, UK; 2GlaxoSmithKline, King of Prussia, PA, USA; 3GlaxoSmithKline, 
Philadelphia, PA, USA
OBJECTIVES: Since the introduction of conjugate vaccines against Haemophilus 
inﬂ uenza type b (Hib) and Streptococcus pneumonia, Neisseria meningitis is the 
leading cause of infant bacterial meningitis. HibMenCY is a new combination vaccine 
being developed for protection against meningococcal groups C and Y (MenCY) and 
Hib. This analysis compared the cost-effectiveness of a four dose HibMenCY vaccina-
tion strategy (2, 4, 6 and 12 months) to Hib vaccination (2, 4, 6 and 12 months) and 
to no Hib or MenCY vaccination from a public health perspective. METHODS: A 
Markov model was used to simulate lifetime events, predicting the likelihood of 
disease with and without speciﬁ c vaccinations. Costs and health consequences were 
built into the model to allow the prediction of lifetime costs and quality-adjusted 
life-years (QALYs). The model was populated with published data throughout, and 
one-way sensitivity analyses were undertaken when there was uncertainty about key 
parameter values. a discount rate of 3% annually was applied. RESULTS: For Hib-
MenCY vaccination relative to Hib alone, 13 additional cases per 100,000 treated 
patients would be prevented, resulting in an additional 104 QALYS saved. The addi-
tional HibMenCY vaccine program cost over Hib alone was $6.61M resulting in a 
cost/QALY of $63,701. For HibMenCY vaccination relative to no Hib or MenCY 
vaccination, 61 cases of meningitis were prevented per 100,000 treated patients, 
resulting in an additional 467 QALYS saved. The additional HibMenCY vaccine 
program cost was $3.14M resulting in a cost/QALY of $6738. CONCLUSIONS: 
When accounting for the ability of the HibMenCY vaccine to prevent infection from 
both pathogens this intervention is estimated to be highly cost-effective. If only the 
incremental beneﬁ t of MenCY is considered, the intervention would result in a better 
cost/QALY than that reported for several widely implemented vaccine strategies. Thus 
infant HibMenCY vaccination is expected to be a cost-effective strategy that provides 
substantial health beneﬁ ts.
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PATIENT PREFERENCES FOR BENEFITS, RISKS, AND WEIGHT OF 
EVIDENCE ASSOCIATED WITH HEPATITIS B TREATMENTS
Mohamed A1, Johnson FR1, Hauber AB1, Lescrauwaet B2, Masterson A2
1RTI Health Solutions, Research Triangle Park, NC, USA; 2Bristol-Myers Squibb, 1420 
Braine—L’Alleud, Belgium
OBJECTIVES: To elicit patient preferences for beneﬁ ts, risks, and weight of evidence 
associated with hepatitis B treatments. METHODS: Adults in 5 countries (France, 
Germany, Spain, Italy, and Turkey) with a self-reported physician diagnosis of hepa-
titis B completed a web-enabled, choice-format, conjoint-analysis survey. The survey 
presented patients with a series of 12 trade-off questions, each including a pair of 
hypothetical hepatitis B medication proﬁ les. Each proﬁ le was deﬁ ned by how long the 
medicine has been studied (weight of evidence), chance that the medicine will work 
well for 5 years (long-term efﬁ cacy), 5-year fracture risk, 5-year risk of kidney disease, 
and cost. Trade-off questions were based on predetermined experimental design with 
known statistical properties. Random-parameters logit was used to estimate a prefer-
ence weight for each attribute level and the mean relative importance of each attribute. 
RESULTS: 560 subjects completed the survey. Patients actively traded between efﬁ -
cacy, side-effect risks, and weight of evidence among the hypothetical hepatitis B 
medication proﬁ les. On an importance-weight scale where 0 is the least important 
outcome and 10 is the most important outcome, the 5-year risk of kidney disease was 
the most important attribute to patients over the range of levels included in the survey 
[95% CI: 7.8–12.2]. The remaining attributes were ranked in decreasing order of 
importance as: chance that the medicine will work well for 5 years (8.9 [95%CI: 
7.1–10.7]), how long the medicine has been studied (8.2 [95%CI: 7.6–8.8]), and 
5-year fracture risk (5.8 [95%CI: 3.6–8.0]). CONCLUSIONS: Although long-term 
efﬁ cacy is important to hepatitis B patients, the 5-year risk of kidney disease,in par-
ticular, also inﬂ uence patients’ treatment choices. Patients are willing to make trad-
eoffs between efﬁ cacy, side-effect risks, and weight of evidence among hepatitis B 
treatments.
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HERPES ZOSTER AND POST-HERPETIC NEURALGIA: CONSIDERATIONS 
FOR A PROSPECTIVE, CROSS-SECTIONAL, PATIENT REPORTED 
OUTCOMES STUDY
Carroll S1, Gater A2, Abetz L2, Demuth D3, Smith F3, Mannan A1
1Sanoﬁ  Pasteur MSD, Maidenhead, Berkshire, UK; 2Mapi Values Ltd, Bollington, Cheshire, UK; 
3Adelphi Real World, Bollington, Cheshire, UK
OBJECTIVES: The pain and discomfort associated with Herpes Zoster (HZ) and 
Post-Herpetic Neuralgia (PHN) can have a substantial negative impact on patients’ 
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Health-Related Quality of Life (HRQoL). To inform the design of a large-scale pro-
spective study of the patient-reported impact of HZ and PHN in the UK, a review of 
published prospective studies was conducted. METHODS: A targeted literature review 
was conducted in MEDLINE® to identify prospective studies investigating the impact 
of HZ and PHN from the patient’s perspective. Searches were limited to studies 
published in English between April 2000 and April 2010. The adequacy of these 
studies in quantifying the burden of HZ and PHN was critically assessed. RESULTS: 
Only a small number of published prospective studies (n = 6) designed to investigate 
the impact of HZ or PHN from patients’ perspectives were identiﬁ ed; one of which 
was conducted in the UK. The HRQoL burden associated with HZ and PHN was 
highlighted in the studies reviewed albeit a number of key points were noted. First, 
the burden of HZ and PHN has not been compared to HRQoL estimates for the 
general population or to those with comparable acute or chronic conditions, thereby 
making interpretation difﬁ cult. Furthermore, studies conducted to date have not 
accounted for the variations in pain and HRQOL burden at different stages of HZ 
presentation. Finally, from the studies reviewed, the pain experienced by patients with 
HZ and PHN is managed with a wide variety of products. However, until now no 
formal assessment of patient satisfaction with these products has been conducted. 
CONCLUSIONS: Although it is known that HZ and PHN can have a negative impact 
on HRQOL, limitations in previous research can be noted. In order to address these 
concerns, a large-scale UK-based prospective study is currently being conducted.
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IMPACT OF HERPES ZOSTER AND POSTHERPETIC NEURALGIA ON 
PATIENTS’ QUALITY OF LIFE
Chassany O1, Gaillat J2, Hanslik T3, Bourhis Y4, Launay O5, Mann C6, Rabaud C7, 
Rogeaux O8, Strady C9, Bouhassira D10
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OBJECTIVES: Incidence and severity of herpes zoster (HZ) increase with age. Posther-
petic neuralgia (PHN) is its most common complication. The study objective was to 
assess the impact of HZ and PHN on daily life and quality of life (QoL) as perceived 
by the patient. METHODS: A 12-month, longitudinal, observational study conducted 
on patients aged ≥50 years with acute HZ (eruptive phase), included by a representa-
tive sample of 644 French general practitioners (GP) between June 2007 and June 
2008. Demographic and disease characteristics and treatment procedures were col-
lected by the GP at the inclusion and at 3, 6 and 12 months. PHN and QoL assess-
ments were performed by telephone interview of patients, at regular time points over 
12 months, using comprehensive and validated questionnaires. RESULTS: a total of 
1358 patients met the selection criteria and 1032 completed the follow-up. Mean age 
was 67.7 ± 10.7 years (62.2% female). Mean time between rash onset and HZ diag-
nosis was 2.6 ± 3.0 days. Most patients (94.1%) were treated with antiviral drugs. 
PHN prevalence at inclusion, 3, 6, and 12 months was 79.6%, 11.6%, 8.5%, and 
6.6% respectively. Mean Zoster Brief Pain Inventory (ZBPI) interference score (range 
= 0–10 worse) at inclusion, 3, 6 and 12 months was 3.1 ± 2.4, 2.9 ± 2.3, 2.5 ± 2.1, 
2.7 ± 2.3 respectively, with main impact on general activity, sleep and mood. Through-
out the 12-month study period, patients with persistent PHN presented lower scores 
on the physical (e.g. at 12 month: 39.7 ± 13.7) and mental (43.6 ± 11.3) component 
summaries of the 12-item short-form health survey (SF-12) than the patients without 
PHN, respectively 46.0 ± 10.6 and 47.8 ± 10.5. Moreover, univariate analysis found 
that among predictive factors at inclusion for PHN were a ZBPI score ≥5 (P < 0.001) 
and a low SF-12 physical component summary (P < 0.001). CONCLUSIONS: This 
large cohort study conﬁ rms the HZ and PHN impact on daily life and quality of life, 
in spite of prompt diagnosis and antiviral treatment.
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EVALUATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 
PATIENTS RECEIVING ANTIRETROVIRAL THERAPY IN MAITAMA 
DISTRICT HOSPITAL, ABUJA NIGERIA
Agu KA1, Okojie O2, Omonaiye O1, Oqua D1, King RC3, Onuoha C1, Muhammadu I1, 
Iyaji PG1
1Howard University PACE Center, Abuja, FCT, Nigeria; 2University of Benin, Benin, Edo, 
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OBJECTIVES: HIV-infected patients demonstrate a health-related quality of life 
(HRQoL) lower than that of the general population. The goals of antiretroviral 
therapy (ART) include the improvement of HRQOL in addition to the reduction of 
symptoms, suppression of the virus, and enhancement of survival. The study evaluated 
HRQoL of HIV-infected patients at months 0 and 6 of receiving ART; and compared 
the HRQoL index of male and female participants. METHODS: The HRQoL of a 
cohort of 150 HIV-infected patients was evaluated at months 0 and 6 of receiving 
ART using SF-36 health survey form. Wilcoxon’s signed ranks test was used to 
compare the HRQoL index between two groups of data. All reported P values were 
2-sided, and P < 0.05 was used to determine statistical signiﬁ cance. RESULTS: The 
mean age of the 150 patients at initiation of antiretroviral treatment was 34.30 (95% 
CI, 32.96–35.64) years; and 59.3% were females. At 6 months follow-up, 118 
(78.7%) ART patients who met the 6th month medication reﬁ ll appointment were 
evaluated for HRQoL. Before commencing ART, the mean HRQoL of participants 
was 71.22 (95%CI, 68.00–74.44) which increased signiﬁ cantly to 90.83 (95%CI, 
88.49–93.17) at 6 months follow up on ART (P < 0.05). The change across all the 
HRQoL domains in the SF-36 instrument was also statistically signiﬁ cant (P < 0.05) 
except for the domains of role limitation due to emotional problems, social functioning 
and pain (p > 0.05). Difference in the HRQoL index of male and female gender at 
months 0 and 6 was not statistically signiﬁ cant (p > 0.05). CONCLUSIONS: There 
was a signiﬁ cant improvement in the mean HRQoL of the participants after 6 months 
of ART; the difference between HRQoL index of male and female participants was 
not signiﬁ cant. Routine evaluation of HRQoL in clinical practice is highly recom-
mended as long-term outcome may be different. 
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MODELING G-DRG REVENUE WHEN HOSPITALIZATION DURATION 
FROM CLINICAL TRIALS IS AVAILABLE: THE CASE OF DORIPENEM 
VERSUS IMIPENEM IN TREATING VENTILATOR-ASSOCIATED 
PNEUMONIA (VAP) IN GERMANY
De Cock E1, Gast C2, Berndt K3, Kubitz N3
1United BioSource Corporation, Barcelona, Spain; 2Axio Research Acquisition Co. LLC, 
Seattle, WA, USA, 3Janssen-Cilag GmbH, Neuss, Germany
OBJECTIVES: Since the introduction of G-DRGs, hospitals have become increasingly 
concerned about impact of changes in clinical practice on hospital costs and revenue. 
We developed an algorithm to estimate expected G-DRG payment by drug, when 
length-of-stay (LOS) data from clinical trials are available. We compared results with 
a scenario where only median values by trial arm are available. METHODS: G-DRG 
attribution is driven by MV duration and intensive care severity score. From a Phase 
III trial comparing doripenem and imipenem (DORI-10), we determined nine catego-
ries of MV duration (ranges based on MV hours resulting in higher-paying G-DRGs). 
Using the Muenster Webgrouper, we obtained G-DRG weights when simultaneously 
varying MV duration and intensive care severity (15 levels) for four clinical proﬁ les. 
For the nine categories and by drug, we obtained percentage patients per group and 
median LOS by type of ward using. Per category, the appropriate G-DRG weight was 
selected based on: chosen proﬁ le, total MV duration, intensive care severity, and total 
LOS. Using distribution of patients by category derived from DORI-10, a weighted 
G-DRG was calculated for each arm, and multiplied by the 2010 base value to yield 
expected G-DRG payment. RESULTS: G-DRG revenue ranged from c2,578 to c8,575 
(across 4 scenarios) to c136,164 for MV ≥ 1800 hours. Using trial-based median LOS 
values, expected G-DRG revenue is c30,397 (all scenarios), with no difference in 
G-DRG revenue in both trial arms. When using the categories approach, expected 
revenue reduction when using doripenem instead of imipenem ranged from c2,084 to 
c2,451. CONCLUSIONS: A G-DRG revenue analysis helps to better understand net 
impact of introducing a new drug on a hospital’s budget. When LOS data (including 
MV) vary by drug and data from clinical studies are available, a classiﬁ cation 
approach enables more reﬁ ned G-DRG revenue estimates as opposed to using median 
values by drug.
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EFFECT OF THE ANTIBIOTICS USE MONITORING PROGRAM FOR THE 
ACUTE UPPER-RESPIRATORY INFECTIONS DISEASE IN KOREAN 
CLINICS
Choi SE1, Park KH1, Lim EA1, Kim SK2
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Agency, Seoul, South Korea
OBJECTIVES: Overuse of antibiotics has been focused for the public health and 
pharmaceutical expenditure in Korea. National Health Insurance introduced the anti-
biotics use monitoring program in 2002. This program includes a monitoring the 
antibiotics prescription rates of medical institutes, a feedback to prescribers, and a 
report to the public via website. This study aims to evaluate the impact of this program 
on the antibiotics prescription rates for the acute upper-respiratory infections (URI) 
in Korea. METHODS: We assessed the antibiotics prescription rates for the acute URI 
(J00-J06) of individual medical institutes from 2002 to 2008. Data was extracted from 
NHI outpatient’s claims database and the ﬁ rst quarter data of each year were selected 
to avoid seasonal variation. To evaluate the effect of program, we assumed the early 
change of prescription rate during 2002–2003 as a baseline, and compared it with 
every year variations of the prescription rate for 2004–2008. Generalized Estimation 
Equation (GEE) model was constructed to investigate the changes in antibiotics pre-
scription. RESULTS: Data included about 49 million claims from 13,211 clinics 
(94.5% of all acute URI claims and 70.5% of all clinics in 2008). Prescription rate 
declined from 72.8% to 55.1% during 2002–2008. The analysis showed that the 
antibiotics use monitoring program reduced 6.11% of antibiotics prescription rate per 
clinic annually (OR: 0.62, 95% CI: 0.61, 0.64, P < 0.0001). The reduced antibiotics 
prescription estimate was average 4.5 million a year. CONCLUSIONS: After monitor-
ing system introduced, the antibiotics prescription rates for acute URI patients have 
continuously decreased in the clinics.
